ASCO: New ‘Armored’ CAR produces significant responses in patients whose cancers don’t respond to current CAR T cell therapies

A new “armored” form of CAR T cell therapy may be able to help patients with non-Hodgkin lymphoma whose cancers do not respond to currently available CAR T cell therapies. The Phase I clinical trial was presented at the 2024 ASCO Annual Meeting.

Could the liver hold the key to better cancer treatments?

Liver inflammation, a common side-effect of cancers elsewhere in the body, has long been associated with worse cancer outcomes and more recently associated with poor response to immunotherapy. Now, a team led by researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania has found a big reason why.

Penn Medicine at the AACR Annual Meeting 2024

Researchers from the Abramson Cancer Center (ACC) and Perelman School of Medicine at the University of Pennsylvania will present data on the latest advances in cancer science and medicine at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.

Invitation to Cover: Perelman School of Medicine Students Meet Their Match

On Friday, March 15, the Perelman School of Medicine (PSOM) at the University of Pennsylvania will celebrate Match Day, the annual event that reveals where graduating medical students will head for residency programs to further their training.

Disparities Persist Across Levels of Surgery Department Leadership in US

Women and those from racial and ethnic groups underrepresented in medicine (URiM) not only occupy few leadership roles in surgical departments but also tend to be clustered into certain leadership roles, according to a new analysis led by researchers from the Perelman School of Medicine at the University of Pennsylvania.

Antibody Treatment Prevents Graft Versus Host Disease, a Major Bone Marrow Transplant Complication, in Advanced Preclinical Tests

An experimental antibody treatment largely prevented a bone marrow transplant complication called graft versus host disease (GVHD) in the intestines, without causing broad immune suppression, in a preclinical study led by researchers from Penn Medicine and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and published today in Science Translational Medicine.

Penn Research Provides Better Understanding into How Genes Make Us Prone To Allergies

New research is bolstering scientific understanding behind why some people are more prone to allergies than others. Researchers in the Perelman School of Medicine at the University of Pennsylvania identified how genetic differences that alter a specific protein called ETS1 can affect our body’s response to allergies. They found that small changes in ETS1 in an animal model can lead to an increased likelihood for allergic reactions that cause inflammation. The findings were published recently in Immunity.

Penn Medicine to Offer Free Cancer Screenings, including 3D Mammograms with Siemens Healthineers, at June Community Events in and around West Philadelphia

As part of a continued focus on making cancer screenings more accessible to the greater Philadelphia community, Penn Medicine is providing free cancer screenings, no insurance required, including advanced 3D mammograms, in West Philadelphia this June.

Four Penn Medicine Abramson Cancer Center Researchers Receive Top AACR Awards

Four distinguished researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania will receive 2023 Scientific Achievement Awards from the American Association for Cancer Research (AACR), during the AACR Annual Meeting 2023.

Penn Medicine Awarded $9.7 Million from The Warren Alpert Foundation for Genetic Counselor Continuing Education Efforts

Penn Medicine has received a $9.7 million grant from The Warren Alpert Foundation (WAF) that will fund continuing education efforts for genetic counselors, to ensure opportunities for continued training that will keep them on the leading edge of their profession interpreting genomic data and explaining its implications to patients.

Stroke, Clot Risk Halved in Heart Disease and Arrhythmia Patients Who Took Blood Thinners Apixaban Versus Rivaroxaban

The new study showed apixaban is superior to rivaroxaban against stroke or systemic embolism in patients with atrial fibrillation and valvular heart disease

Penn Research Finds Psoriasis Medication Apremilast Leads to Fat Loss in People with Psoriasis

Apremilast (brand name Otezla) has helped psoriasis patients achieve clearer skin and ease the symptoms of their psoriatic arthritis. Now, new data from researchers at the Perelman School of Medicine at the University of Pennsylvania shows it could also help people with psoriasis shed unhealthy body fat and therefore improve cardiovascular health, a well-known vulnerability for those with psoriasis.

Hormone Infusion Improves Pancreatic Insulin Production in Cystic Fibrosis Patients with or at Risk for Diabetes

Medication therapy based on the hormone glucagon-like peptide-1(GLP-1) may help regulate natural insulin production in cystic fibrosis, potentially offering a better way to prevent and ultimately manage diabetes than daily insulin injections

Piezo1 Possible Key to Supporting Muscle Regeneration in Duchenne Muscular Dystrophy

Tracing the impact of a single protein, Piezo1, Penn researchers found that restoring it in muscles affected by Duchenne muscular dystrophy could improve their ability to heal efficiently

Penn Medicine’s Pavilion Marks a Healthcare ‘First’ with Prestigious LEED Gold Building Certification for Sustainability

Penn Medicine’s new Pavilion on the Hospital of the University of Pennsylvania’s campus has broken new ground for sustainable healthcare construction and design with Leadership in Energy and Environmental Design (LEED) Healthcare Gold Certification.

Penn Center for Musculoskeletal Disorders NIH Grant Renewed for $4 Million

The United States’ longest-running NIH-sponsored musculoskeletal research center will receive $4M to continue its studies of everything from ligament tears to osteoarthritis

AACI Members Choose Winn as President-Elect

Robert Winn, MD, director of VCU Massey Cancer Center, has been elected by the members of the Association of American Cancer Institutes (AACI) to serve as vice president/president-elect of AACI’s board of directors.